ClinicalTrials.gg
RecruitingNCT05010902Updated Jul 5, 2024

Pregnancy Cohort in Multiple Sclerosis (MS)

An observational study in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS), sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2013; still recruiting 13 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Charite University, Berlin, Germany.

Started
2013
with 2 others
Observational
5 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, this one is one of 3 that started in 2013, is one of 5 observational ones, and was the 17th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life. In this prospective observational study, we obtain data on the outcome of pregnancies in MS patients and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.

03

Conditions studied

  • Multiple Sclerosis (MS)
  • Clinically Isolated Syndrome (CIS)

Browse trials for

Keywords

  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients will be recruted at neurological outpatient clinics and neurological clinics of the Charité and neurologists' medical practices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years
  • signed
  • diagnosis of multiple sclerosis or clinically isolated syndrome

Exclusion criteria

Exclusion Criteria:

  • comorbidities
  • for MRI, e.g. pacemaker, metal implants, allergy against gadolinium
  • alcohol or drug abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Multiple sclerosis

    Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis

06

What researchers measure

Primary outcomes

  1. Time until relapse

    Time (in days) until relapse during the observation period

    Time frame: 12 months after delivery compared to baseline

Secondary outcomes

  1. Number of T2 lesions

    Number of T2 lesions in spinal and cerebral magnetic resonance imaging

    Time frame: 12 months after delivery compared to baseline

  2. Number of gadolinium enhancing lesions

    Number of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging

    Time frame: 12 months after delivery compared to baseline

  3. Volume of T2 lesions

    Volume of T2 lesions in spinal and cerebral magnetic resonance imaging

    Time frame: 12 months after delivery compared to baseline

  4. Volume of gadolinium enhancing lesions

    Volume of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging

    Time frame: 12 months after delivery compared to baseline

  5. Change in immune cell phenotypes

    Change in immune cell phenotypes of peripheral blood mononuclear cells (PBMC)

    Time frame: 12 months after delivery compared to baseline

  6. Galectin-1

    Change in serum galectin-1 concentration measured by ELISA

    Time frame: 12 months after delivery compared to baseline

  7. Galectin-3

    Change in serum galectin-3 concentration measured by ELISA

    Time frame: 12 months after delivery compared to baseline

  8. Galectin-9

    Change in serum galectin-9 concentration measured by ELISA

    Time frame: 12 months after delivery compared to baseline

  9. Neurofilament (NfL)

    Change in neurofilament serum concentration by using Simoa NfL assay

    Time frame: 12 months after delivery compared to baseline

  10. Pro-inflammatory interleukin-17

    Change in interleukin-17 serum concentration assessed by ELISA

    Time frame: 12 months after delivery compared to baseline

  11. Anti-inflammatory interleukin-10

    Change in anti-inflammatory interleukin-10 serum concentration assessed by ELISA

    Time frame: 12 months after delivery compared to baseline

  12. Autoantibody profiling

    Identification and quantification of autoantibodies by using protein microarray and ELISA

    Time frame: 12 months after delivery compared to baseline

  13. Fecal microbiome composition

    Composition of fecal microbiome measured by 16S Sequencing

    Time frame: 12 months after delivery compared to baseline

  14. Thickness of the retinal nerve fibre layer

    Thickness of the retinal nerve fibre layer by Optical Coherence Tomography (OCT)

    Time frame: 12 months after delivery (compared to baseline)

  15. Total macular volume (TMV)

    Total macular volume by Optical Coherence Tomography (OCT)

    Time frame: 12 months after delivery compared to baseline

  16. Mini-International Neuropsychiatric Interview (M.I.N.I.) German Version 5.0.0 Module A-C

    Structured diagnostic interview to assess depression, dysthymia and suicidality

    Time frame: 12 months after delivery compared to baseline

  17. Montgomery-Asberg Depression Rating Scale (MADRS)

    Rating of ten depression related symptoms on a scale from 0 to 6 (higher numbers indicate more severe symptoms)

    Time frame: 12 months after delivery compared to baseline

  18. Beck Depression Inventory (BDI-II)

    Rating of 21 depression related symptoms on a scale from 0 to 3 (higher numbers indicate more severe symptoms)

    Time frame: 12 months after delivery compared to baseline

  19. Edinburgh Postpartum Depression Scale (EPDS)

    Self-report survey containing 10 items, each item is rated 0-3 (higher scores indicate a higher probability of postpartum depression)

    Time frame: 12 months after delivery compared to baseline

  20. Modified Fatigue Inventory Scale (MFIS)

    Self-report survey containing 21 items, each item is rated 0-4 (higher scores indicate a greater impact of fatigue on a person's activities)

    Time frame: 12 months after delivery compared to baseline

  21. Fatigue Severity Scale (FSS)

    A self-report survey consisting of 11 items, each item ranges from 1 to 7 (higher scores indicate higher levels of fatigue)

    Time frame: 12 months after delivery compared to baseline

  22. Visual Fatigue Analogue Scale (VFAS)

    A self-administered, single scale indication measuring visual fatigue, ranging from 0 to 100 (higher scores indicate worse fatigue)

    Time frame: 12 months after delivery compared to baseline

  23. Short-Form Health Survey (SF-36)

    A self-report survey measuring health in eight dimensions (higher scores indicate less disability)

    Time frame: 12 months after delivery compared to baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2013 (actual). Primary completion is estimated for Dec 2025, 155 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 155 months is above that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2021
First posted
Aug 18, 2021
StartActual
Jan 1, 2013
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05010902
Responsible party
Nadja Siebert (Principal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
Aug 18, 2021
Start date
Jan 1, 2013
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 5, 2024

Study contacts

Nadja Siebert, MD
Contact
nadja.siebert@charite.de
Friedemann Paul, Prof.
Contact
friedemann.paul@charite.de
Nadja Siebert, MD
principal investigator · Experimental & Clinical Research Unit, Charité Universitätsmedizin Berlin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion